OM
STRO icon

Opaleye Management’s Sutro Biopharma STRO Stock Holding History

Opaleye Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-190,671
Closed -$4.75M – 65
2026
Q1 		$4.75M Hold
190,671
– – 0.63% 32
2025
Q4 		$2.21M Buy
+190,671
New +$1.81M 0.29% 44
2024
Q1 		– Sell
-30,149
Closed -$1.29M – 58
2023
Q4 		$1.29M Buy
+30,149
New +$957K 0.34% 42
2023
Q3 		– Sell
-30,700
Closed -$1.43M – 50
2023
Q2 		$1.43M Buy
+30,700
New +$1.53M 0.34% 38
2022
Q2 		– Sell
-8,998
Closed -$740K – 54
2022
Q1 		$740K Sell
8,998
-59,002
-87% -$5.61M 0.23% 43
2021
Q4 		$10.1M Buy
68,000
+14,220
+26% +$2.55M 2.15% 16
2021
Q3 		$10.2M Buy
53,780
+4,090
+8% +$778K 1.9% 16
2021
Q2 		$9.24M Buy
49,690
+15,495
+45% +$3.03M 1.53% 22
2021
Q1 		$7.78M Buy
34,195
+1,975
+6% +$469K 1.14% 27
2020
Q4 		$7M Buy
32,220
+17,620
+121% +$2.92M 0.91% 29
2020
Q3 		$1.47M Buy
+14,600
New +$1.38M 0.29% 46

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Opaleye Management's STRO Position: Q2 2026 in Review

Opaleye Management sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 190,671 shares — an estimated $4.75M sold.

Opaleye Management first reported a position in STRO in Q3 2020 and held it in 11 quarters. The position peaked at $10.2M in Q3 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Opaleye Management reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
  • Opaleye Management sold 190,671 Sutro Biopharma shares in Q2 2026, an estimated $4.75M.
  • Opaleye Management first reported a position in Sutro Biopharma in Q3 2020 and held it in 11 quarters.
  • Opaleye Management's Sutro Biopharma position peaked at $10.2M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.